Anna van Muyden is a seasoned professional in clinical development and oncology, currently serving as Cell Tx Development Team Leader and Head of Clinical Science Oncology at Galapagos since June 2022. With a strong background in advancing innovative cell therapy solutions, Anna oversees the development of multiple CAR T products across hematological malignancies in the EU and US. Prior experience includes pivotal roles at CellPoint, where accomplishments included directing clinical development and shaping regulatory strategies for CAR-T products, and leading Phase I clinical trials at Gadeta and UMC Utrecht. Anna holds a Master of Science in Science and Business Management and a Bachelor of Science in Biomedical Sciences from Utrecht University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices